Моликсан®

General characteristics. Structure:

Active ingredient: 10 mg, 30 mg or 60 mg of inosine a dinatrium glycyl-tsisteinil-glutamate in 1 ampoule.

Excipients: acetate sodium trihydrate, acetic acid divorced (to pH 6), water for and.

Drug possesses immunomodulatory, antiviral and hepatoprotective action.

Pharmacological properties:

Pharmacodynamics. Represents the organic salt including inosine (a purine component) and a dinatrium glycyl-tsisteinil-glutamate (a peptide component) in the ratio 1:1.

Моликсан® regulates thiol - disulfide exchange of hepatocytes, induces an expression of enzymes of the first and second phases of a detoxication of xenobiotics, suppresses DNA replication - and the RNA viruses causing hepatitises B and C stimulates products of interferon α and γ with macrophages of a liver, interleykina-2 T lymphocytes.

Cytoprotective and immunomodulatory activities of peptide and purine components of the drug Moliksan® lead to inhibition of a cytolysis of hepatocytes, permission of inflammatory process at toxic and virus defeats of cells of a liver.

Peptide and purine components of the drug Moliksan® indirectly influence metabolism, processes of proliferation, a differentiation and apoptosis of cells of a liver, promoting recovery of normal structure of hepatic fabric.

Pharmacokinetics. The drug Moliksan® pharmacokinetics at in introduction in a dose of 1 mg/kg is described by dvukhchastevy model with the following indicators on a peptide component of organic salt of the drug Moliksan®: Cmax of a peptide component in a blood plasma - 170-180 mkg/ml; a constant of elimination of a peptide component - 0.085 min.-1; bioavailability of a peptide component - 90%; the general clearance of a peptide component - 20 ml/kg/min.; the average time of deduction of a peptide component - 6-8 min.; T1/2 of a peptide component - 15-20 min.

Components of organic salt of the drug Moliksan®, peptide and purine component, are metabolized in bodies and body tissues to amino acids and derivative purine bases, removed by kidneys.

Indications to use:

— an acute and chronic viral hepatitis In, Page.

Route of administration and doses:

Solution is intended for in/in and introductions in oil. At an acute viral hepatitis In Moliksan® enter in/in or in oil once in a dose of 10 mg/days, every other day, throughout all course of symptomatic and disintoxication therapy.

At severe forms of an acute viral hepatitis In Moliksan® enter in/in or in oil once in a dose of 20 mg/days, daily, throughout all course of symptomatic and disintoxication therapy.

As a part of complex antiviral therapy of a chronic viral hepatitis In Moliksan® enter in/in or in oil once 30 mg/days, 3 times in a dose a week, every other day throughout all course of specific antiviral therapy.

In monotherapies of a chronic viral hepatitis In, resistant to means of specific antiviral therapy or at impossibility of its carrying out on medical indications, Moliksan® 24 weeks enter in/in or in oil once 30 mg/days, 3 times in a dose a week, every other day, a course of treatment.

As a part of complex antiviral therapy of a chronic viral hepatitis With Moliksan® enter in/in or in oil once 60 mg/days, 3 times in a dose a week, every other day throughout all course of specific antiviral therapy.

In monotherapies of a chronic viral hepatitis With, resistant to means of specific antiviral therapy or at impossibility of its carrying out on medical indications, Moliksan® 24 weeks enter in/in or in oil once 60 mg/days, 3 times in a dose a week, every other day, a course of treatment.

Features of use:

Use at pregnancy and feeding by a breast. Use of drug at pregnancy and in the period of a lactation is contraindicated.

Use at abnormal liver functions. The Page is applied to treatment of an acute and chronic viral hepatitis In.

Use for children. It is contraindicated to children.

Special instructions. Treatment by drug has to be carried out under regular control of the doctor.

As solution carrier for in/in introductions use isotonic solution of sodium of chloride or 5% glucose solution. As solvent for in/in introductions use 0.9% solution of sodium of chloride or 5% dextrose solution.

Influence on ability to driving of motor transport and to control of mechanisms. Negative influence on ability of control of vehicles, mechanisms is noted.

Side effects:

Allergic reactions: in the place of an injection the local hyperemia, burning, a swelling is possible. At certain patients slight increase of body temperature (to 37.1-37.5 °C), morbidity in the place of an injection of drug can be observed (in this case the drug is administered together with 1-2 ml 0.25% of solution of Procainum).

Interaction with other medicines:

Medicinal interaction of the drug Moliksan® with other medicines is not revealed.

Contraindications:

— pregnancy;

— breastfeeding period;

— children's age;

— hypersensitivity to drug components.

Overdose:

About cases of overdose of the drug Moliksan® it was not reported.

Storage conditions:

Drug should be stored in protected from light, in the place, unavailable to children, at a temperature not above 25 °C. A period of validity - 3 years.

Issue conditions:

According to the recipe

Packaging:

2 ml - ampoules glass (5) - planimetric strip packagings (1) - packs cardboard.
2 ml - ampoules glass (5) - planimetric strip packagings (2) - packs cardboard.